A detailed history of Lpl Financial LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 12,302 shares of ARCT stock, worth $215,408. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,302
Previous 12,872 4.43%
Holding current value
$215,408
Previous $313,000 8.95%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$18.08 - $25.38 $10,305 - $14,466
-570 Reduced 4.43%
12,302 $285,000
Q2 2024

Aug 07, 2024

SELL
$24.35 - $44.39 $11,420 - $20,818
-469 Reduced 3.52%
12,872 $313,000
Q1 2024

May 10, 2024

SELL
$31.23 - $42.99 $3,123 - $4,299
-100 Reduced 0.74%
13,341 $450,000
Q4 2023

Feb 14, 2024

SELL
$17.71 - $32.97 $10,094 - $18,792
-570 Reduced 4.07%
13,441 $423,000
Q3 2023

Nov 13, 2023

BUY
$25.44 - $37.35 $356,439 - $523,310
14,011 New
14,011 $357,000
Q2 2022

Aug 12, 2022

SELL
$12.26 - $31.17 $159,882 - $406,487
-13,041 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$17.64 - $39.57 $70,471 - $158,082
3,995 Added 44.16%
13,041 $352,000
Q4 2021

Feb 14, 2022

BUY
$34.2 - $47.56 $12,209 - $16,978
357 Added 4.11%
9,046 $335,000
Q3 2021

Nov 15, 2021

SELL
$27.88 - $58.25 $11,430 - $23,882
-410 Reduced 4.51%
8,689 $415,000
Q2 2021

Aug 13, 2021

BUY
$25.79 - $42.11 $79,433 - $129,698
3,080 Added 51.17%
9,099 $308,000
Q1 2021

May 14, 2021

BUY
$38.75 - $86.92 $24,645 - $55,281
636 Added 11.81%
6,019 $249,000
Q4 2020

Feb 12, 2021

BUY
$34.61 - $123.66 $186,305 - $665,661
5,383 New
5,383 $234,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $465M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.